CD274 and non-small cell lung carcinoma: These results indicate that different monotherapies with anti-PD-L1 agents are being attempted, but more clinical studies are required to establish the ability for neoadjuvant immunotherapy to improve the survival of patients with early-stage NSCLC (Table 1).